News

Jun 4, 2021

Mitotherapeutix Awarded $2.2 Million SBIR Grant from the National Institutes of Health for siRNA NASH Candidates

Apr 19, 2021

Research, Sponsored Programs, and Innovation Financial Conflict of Interest in Research Policy

Sep 24, 2020

Mitotherapeutix Announces Positive Results from Pre-Clinical Liver Biopsy Study in Cynomolgus Monkeys

Aug 22, 2020

Researchers discover promising remedy to battle epidemic of liver disease

Aug 10, 2020

Nature Communications Editors’ Highlights

July 9, 2020

New, Promising Therapy to Fight Epidemic of Liver Disease Discovered

July 8, 2020

Inhibition of MCJ Transmembrane Protein Studied as NAFLD Treatment

July 7, 2020

Researchers Find Promising Therapy to Fight Epidemic of Liver Disease

July 3, 2020

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

Publications

Barbier-Torres., et al., Silencing Hepatic MCJ attenuates NAFLD by increasing mitochondrial fatty acid oxidation. Nature Communications., Jul 2020., (11) 3360., 1-15. https://pubmed.ncbi.nlm.nih.gov/32620763/

Barbier-Torres., et al., The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nature Communications., Dec 2017., (8) 2068., 2-11. https://pubmed.ncbi.nlm.nih.gov/29233977/

Champagne D.P., et al., Fine-Tuning of CD8+ T Cell Mitochondrial Metabolism by the Respiratory Chain Repressor MCJ Dictates Protection to Influenza Virus. Immunity., Jun 2016., (44). 1299-1311. https://pubmed.ncbi.nlm.nih.gov/27234056/

Hatle K.M., et al., MCJ/DnaJC15, an Endogenous Mitochondrial Repressor of the Respiratory Chain That Controls Metabolic Alterations. Jun 2013., Vol 33 (11)., 2302-2314. https://pubmed.ncbi.nlm.nih.gov/23530063/